OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BIOVICB58

Biovica International AB

Biotechnology & Medical ResearchVerified

Biovica's capital structure is characterized by a high proportion of equity, with total equity of 96.64 million SEK and long-term debt of 7.83 million SEK, resulting in a debt-to-equity ratio of 0.08. The company maintains a strong liquidity position, with cash and equivalents of 79.41 million SEK and a current ratio of 3.11, indicating a robust ability to meet short-term obligations. Profitability metrics are negative, with a return on equity of -40.91% and a return on assets of -30.08%. These figures are significantly below the industry median for biotechnology firms, which typically exhibit positive returns during growth phases. The company reported a net loss of 39.53 million SEK, driven by a substantial operating loss of 41.49 million SEK. Geographically, Biovica's revenue is concentrated in a limited number of markets, with no detailed breakdown provided in the available data. The company's exposure to specific regions or customer segments is not disclosed, but its reliance on a narrow product portfolio increases vulnerability to market shifts. Growth prospects are mixed. The company's current fiscal year revenue is 18.99 million SEK, with analyst estimates projecting a significant increase to 40 million SEK in the next fiscal year. However, the company's operating cash flow is negative at -114.57 million SEK, and free cash flow is also negative at -37.31 million SEK, indicating ongoing cash burn despite revenue growth. Risk factors include the company's unprofitable operations and high cash burn rate, which could necessitate additional financing. The risk assessment indicates low dilution potential, but the company's liquidity risk is classified as low, supported by its strong cash reserves. No immediate filing-based liquidity or dilution flags were detected. Recent events include the publication of financial results showing continued losses and a lack of positive earnings surprises. The company has not issued new shares recently, and there are no indications of upcoming equity offerings or material regulatory changes affecting its operations.

30-day price · BIOVICB(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyBiovica International AB
TickerBIOVICB.ST
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Biovica International AB develops and commercializes diagnostic products for the detection of neurodegenerative diseases, primarily through its proprietary biomarker technology.

Classification. Biovica is classified in the Biotechnology & Medical Research industry under the Healthcare economic sector, with a confidence level of 0.92 based on verified market data.

Biovica's capital structure is characterized by a high proportion of equity, with total equity of 96.64 million SEK and long-term debt of 7.83 million SEK, resulting in a debt-to-equity ratio of 0.08. The company maintains a strong liquidity position, with cash and equivalents of 79.41 million SEK and a current ratio of 3.11, indicating a robust ability to meet short-term obligations. Profitability metrics are negative, with a return on equity of -40.91% and a return on assets of -30.08%. These figures are significantly below the industry median for biotechnology firms, which typically exhibit positive returns during growth phases. The company reported a net loss of 39.53 million SEK, driven by a substantial operating loss of 41.49 million SEK. Geographically, Biovica's revenue is concentrated in a limited number of markets, with no detailed breakdown provided in the available data. The company's exposure to specific regions or customer segments is not disclosed, but its reliance on a narrow product portfolio increases vulnerability to market shifts. Growth prospects are mixed. The company's current fiscal year revenue is 18.99 million SEK, with analyst estimates projecting a significant increase to 40 million SEK in the next fiscal year. However, the company's operating cash flow is negative at -114.57 million SEK, and free cash flow is also negative at -37.31 million SEK, indicating ongoing cash burn despite revenue growth. Risk factors include the company's unprofitable operations and high cash burn rate, which could necessitate additional financing. The risk assessment indicates low dilution potential, but the company's liquidity risk is classified as low, supported by its strong cash reserves. No immediate filing-based liquidity or dilution flags were detected. Recent events include the publication of financial results showing continued losses and a lack of positive earnings surprises. The company has not issued new shares recently, and there are no indications of upcoming equity offerings or material regulatory changes affecting its operations.
Key takeaways
  • Biovica maintains a strong liquidity position with a current ratio of 3.11 and 79.41 million SEK in cash and equivalents.
  • The company is unprofitable, with a return on equity of -40.91% and a return on assets of -30.08%.
  • Analysts project a significant revenue increase to 40 million SEK in the next fiscal year, but current operating cash flow is negative.
  • The company's debt-to-equity ratio is low at 0.08, indicating a conservative capital structure.
  • No immediate liquidity or dilution risks are flagged, but the company's unprofitability and cash burn rate remain concerns.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$1.9M
Gross profit-$8.8M
Operating income-$41.5M
Net income-$39.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$114.6M
CapEx-$146.0k
Free cash flow-$37.3M
Total assets$131.4M
Total liabilities$34.8M
Total equity$96.6M
Cash & equivalents$79.4M
Long-term debt$7.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$2.1M-$40.2M-$39.5M-$36.9M
FY-3$2.0M-$60.1M-$60.0M-$57.0M
FY-2$3.4M-$110.5M-$110.5M-$105.1M
FY-1$7.3M-$126.8M-$124.8M-$115.5M
FY0$8.6M-$85.8M-$87.6M-$79.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$192.7M$182.7M$145.4M
FY-3$151.6M$124.1M$89.8M
FY-2$172.3M$138.6M$12.2M
FY-1$131.4M$96.6M$12.8M
FY0$64.9M$43.2M$0.00
PeriodOCFCapExFCFSBC
FY-4-$34.4M-$3.6M-$36.9M
FY-3-$52.1M-$3.4M-$57.0M
FY-2-$94.6M-$2.8M-$105.1M
FY-1-$114.6M-$146.0k-$115.5M
FY0-$85.4M-$287.0k-$79.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.9M-$41.5M-$39.5M-$37.3M
FQ-6$1.7M-$23.6M-$22.9M-$20.5M
FQ-5$2.3M-$19.8M-$21.2M-$19.0M
FQ-4$2.3M-$22.2M-$22.8M-$20.8M
FQ-3$2.3M-$20.3M-$20.8M-$18.7M
FQ-2$2.6M-$19.3M-$17.8M-$15.8M
FQ-1$2.7M-$15.0M-$15.1M-$13.0M
FQ0$3.3M-$17.8M-$17.9M-$15.9M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$131.4M$96.6M$79.4M
FQ-6$113.9M$89.3M$65.2M
FQ-5$108.4M$86.9M$61.9M
FQ-4$86.9M$64.5M$43.5M
FQ-3$64.9M$43.2M$24.4M
FQ-2$56.8M$25.7M$16.3M
FQ-1$138.6M$123.8M$100.7M
FQ0$126.5M$105.9M$88.2M
PeriodOCFCapExFCFSBC
FQ-7-$114.6M-$146.0k-$37.3M
FQ-6-$29.0M$0.00-$20.5M
FQ-5-$50.1M$0.00-$19.0M
FQ-4-$67.5M-$209.0k-$20.8M
FQ-3-$85.4M-$287.0k-$18.7M
FQ-2-$17.2M-$144.0k-$15.8M
FQ-1-$35.3M-$147.0k-$13.0M
FQ0-$46.8M-$186.0k-$15.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$96.6M
Net cash$71.6M
Current ratio3.1
Debt/Equity0.1
ROA-30.1%
ROE-40.9%
Cash conversion2.9%
CapEx/Revenue-7.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricBIOVICBActivity
Op margin-2184.8%2.4% medp25 -91.8% · p75 12.5%bottom quartile
Net margin-2081.7%1.2% medp25 -98.4% · p75 10.4%bottom quartile
Gross margin-464.9%45.6% medp25 29.8% · p75 66.7%bottom quartile
CapEx / revenue-7.7%-5.2% medp25 -15.8% · p75 -1.7%below median
Debt / equity8.0%9.3% medp25 0.1% · p75 43.8%below median
Observations
IR observations
Mean price target0.70 SEK
Median price target0.70 SEK
High price target0.70 SEK
Low price target0.70 SEK
Mean EPS estimate-0.18 SEK
Last actual EPS-0.88 SEK
Mean revenue estimate40,000,000 SEK
Last actual revenue8,619,000 SEK
Mean EBIT estimate-49,000,000 SEK
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 23:24 UTC#5322b1f9
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 12:26 UTCJob: 0e5f0c8c